- Home
- LAUR vs KNSA Comparison
LAUR vs KNSA Comparison
Compare LAUR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LAUR | KNSA |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.9B |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LAUR | KNSA |
|---|---|---|
| Price | $37.92 | $63.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $39.63 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 1.3M | 890.0K |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $1,484,288,000.00 | $677,564,000.00 |
| Revenue This Year | $14.58 | $37.48 |
| Revenue Next Year | $7.85 | $17.87 |
| P/E Ratio | ★ N/A | $238.85 |
| Revenue Growth | 19.48 | ★ 60.09 |
| 52 Week Low | $21.53 | $26.27 |
| 52 Week High | $38.28 | $64.81 |
Technical Indicators
Market Signals| Indicator | LAUR | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 66.08 | 72.76 |
| Support Level | $33.10 | $40.67 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.26 | 2.39 |
| MACD | 0.05 | 1.09 |
| Stochastic Oscillator | 97.63 | 97.96 |
Price Performance
Historical ComparisonAbout LAUR Laureate Education Inc.
Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions. Its reportable segments include Peru and Mexico, of which Mexico derives maximum revenue. Geographically, the company operates in Mexico, Peru and United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.